List view / Grid view
24 May 2016 | By Victoria White, Digital Content Producer
As part of the update, the black triangle symbol, indicating that additional safety monitoring for Champix in the UK was required, has been removed...
13 May 2016 | By Victoria White, Digital Content Producer
Pfizer has announced results of two Phase III studies demonstrating the immunogenicity of Trumenba against invasive meningococcal B strains...
22 April 2016 | By Victoria White, Digital Content Producer
EAGLES compared the neuropsychiatric safety and efficacy of varenicline and bupropion to placebo and nicotine patch to help people quit smoking...
20 April 2016 | By Victoria White, Digital Content Producer
Pfizer has announced positive top-line results from the Phase III PALOMA-2 trial for Ibrance (palbociclib) in breast cancer...
6 April 2016 | By Victoria White
The decision was driven by the actions announced by the US Department of Treasury, which the companies concluded qualified as an “Adverse Tax Law Change”...
24 March 2016 | By Victoria White, European Pharmaceutical Review
We’ve created an infographic on counterfeit drugs, highlighting some of the actions taken to counter this global problem...
24 March 2016 | By Victoria White
Xeljanz is the only oral Janus kinase (JAK) inhibitor approved in more than 45 countries around the world for the treatment of moderate to severe RA...
21 March 2016 | By Victoria White
Results from OCTAVE Induction 1 and 2, evaluating the efficacy and safety of oral tofacitinib in inducing remission in ulcerative colitis, were presented at ECCO...
14 March 2016 | By Victoria White
The approval is based on a Phase I study that included 50 patients with ROS1-positive metastatic NSCLC treated with 250 mg of Pfizer's Xalkori (crizotinib) orally twice daily...
23 February 2016 | By Victoria White
Ibrance is approved for the treatment of HR+, HER2- advanced or metastatic breast cancer in combination with fulvestrant in women with disease progression following endocrine therapy...
12 February 2016 | By Victoria White
Infliximab is a tumour necrosis factor alpha (TNF-alpha) inhibitor used to treat a range of autoimmune diseases including rheumatoid arthritis and psoriasis...
8 February 2016 | By Victoria White
The close of the transaction to combine Pfizer and Allergan is expected in the second half of 2016, and is subject to certain conditions...
1 February 2016 | By Victoria White
Andexanet alfa is designed to reverse the anticoagulant activity of Factor Xa inhibitors, including Eliquis (apixaban)...
Mega mergers, 3D printed drugs, a call for action on antimicrobial resistance: 2015 certainly was an interesting year for the pharmaceutical industry. Here we pick a selection of the top stories that hit the headlines.
26 January 2016 | By Victoria White
NICE recommends the seven biological disease modifying drugs as options for treating severe rheumatoid arthritis which has not responded to intensive therapy with a combination of conventional DMARDs...
